{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:21:19Z","timestamp":1790108479186,"version":"4.0.1"},"reference-count":30,"publisher":"The Society for Free Radical Research Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Biochem. Nutr."],"published-print":{"date-parts":[[2021,5,1]]},"DOI":"10.3164\/jcbn.20-112","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T22:06:42Z","timestamp":1616623602000},"page":"235-242","source":"Crossref","is-referenced-by-count":8,"title":["Oxidative stress induces EGFR inhibition-related skin cell death"],"prefix":"10.3164","volume":"68","author":[{"given":"Midori","family":"Morita","sequence":"first","affiliation":[{"name":"Division of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahiro","family":"Iizuka-Ohashi","sequence":"additional","affiliation":[{"name":"Division of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Molecular-Targeting Prevention, Kyoto Prefectural University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Molecular-Targeting Prevention, Kyoto Prefectural University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikage","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Kakibuchi","sequence":"additional","affiliation":[{"name":"Division of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuki","family":"Kitano","sequence":"additional","affiliation":[{"name":"Division of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Ouchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Saiseikai Shiga Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"Division of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Division of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1739","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 15\u201331.","DOI":"10.1517\/14728222.2011.648617"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel) 2017; 9: 52.","DOI":"10.3390\/cancers9050052"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999; 17: 259\u2013269.","DOI":"10.1023\/A:1006384521198"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol 2003; 194: 13\u201319.","DOI":"10.1002\/jcp.10194"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 Suppl 4: S9\u2013S15.","DOI":"10.1016\/S0959-8049(01)00231-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Sihto H, Puputti M, Pulli L, et al. Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors. J Mol Med (Berl) 2005; 83: 976\u2013983.","DOI":"10.1007\/s00109-005-0699-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183\u2013232.","DOI":"10.1016\/1040-8428(94)00144-I"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Holcmann M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol 2015; 2: e1004969.","DOI":"10.1080\/23723556.2015.1004969"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803\u2013812.","DOI":"10.1038\/nrc1970"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491\u2013500.","DOI":"10.1016\/S1470-2045(05)70243-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Chanprapaph K, Vachiramon V, Rattanakaemakorn P. Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol Res Pract 2014; 2014: 734249.","DOI":"10.1155\/2014\/734249"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Pastore S, Lulli D, Girolomoni G. Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Arch Toxicol 2014; 88: 1189\u20131203.","DOI":"10.1007\/s00204-014-1244-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Mascia F, Lam G, Keith C, et al. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci Transl Med 2013; 5: 199ra110.","DOI":"10.1126\/scitranslmed.3005773"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 2013; 5: 199ra111.","DOI":"10.1126\/scitranslmed.3005886"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Uchi H, Terao H, Koga T, Furue M. Cytokines and chemokines in the epidermis. J Dermatol Sci 2000; 24 Suppl 1: S29\u2013S38.","DOI":"10.1016\/S0923-1811(00)00138-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163: 303\u2013312.","DOI":"10.1016\/S0002-9440(10)63654-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Iizuka-Ohashi M, Watanabe M, Sukeno M, et al. Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells. Oncotarget 2018; 9: 19597\u201319612.","DOI":"10.18632\/oncotarget.24696"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Miyamoto K, Watanabe M, Boku S, et al. xCT Inhibition increases sensitivity to vorinostat in a ROS-dependent manner. Cancers (Basel) 2020; 12: 827.","DOI":"10.3390\/cancers12040827"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Poirier Y, Antonenkov VD, Glumoff T, Hiltunen JK. Peroxisomal beta-oxidation\u2014a metabolic pathway with multiple functions. Biochim Biophys Acta 2006; 1763: 1413\u20131426.","DOI":"10.1016\/j.bbamcr.2006.08.034"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci 2014; 39: 347\u2013354.","DOI":"10.1016\/j.tibs.2014.06.005"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Kuehne A, Emmert H, Soehle J, et al. Acute activation of oxidative pentose phosphate pathway as first-line response to oxidative stress in human skin cells. Mol Cell 2015; 59: 359\u2013371.","DOI":"10.1016\/j.molcel.2015.06.017"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Sheipouri D, Grant R, Bustamante S, Lovejoy D, Guillemin GJ, Braidy N. Characterisation of the kynurenine pathway in skin-derived fibroblasts and keratinocytes. J Cell Biochem 2015; 116: 903\u2013922.","DOI":"10.1002\/jcb.25019"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Sheipouri D, Braidy N, Guillemin GJ. Kynurenine pathway in skin cells: implications for UV-induced skin damage. Int J Tryptophan Res 2012; 5: 15\u201325.","DOI":"10.4137\/IJTR.S9835"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Gr\u00f6ne A. Keratinocytes and cytokines. Vet Immunol Immunopathol 2002; 88: 1\u201312.","DOI":"10.1016\/S0165-2427(02)00136-8"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Bashir MM, Sharma MR, Werth VP. TNF-alpha production in the skin. Arch Dermatol Res 2009; 301: 87\u201391.","DOI":"10.1007\/s00403-008-0893-7"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Howie SE, Aldridge RD, McVittie E, Forsey RJ, Sands C, Hunter JA. Epidermal keratinocyte production of interferon-gamma immunoreactive protein and mRNA is an early event in allergic contact dermatitis. J Invest Dermatol 1996; 106: 1218\u20131223.","DOI":"10.1111\/1523-1747.ep12348507"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Postovit L, Widmann C, Huang P, Gibson SB. Harnessing oxidative stress as an innovative target for cancer therapy. Oxid Med Cell Longev 2018; 2018: 6135739.","DOI":"10.1155\/2018\/6135739"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Teppo HR, Soini Y, Karihtala P. Reactive oxygen species-mediated mechanisms of action of targeted cancer therapy. Oxid Med Cell Longev 2017; 2017: 1485283.","DOI":"10.1155\/2017\/1485283"},{"key":"29","unstructured":"29 World Health Organization Model List of Essential Medicines. The Expert Committee on the Selection and Use of Essencial Medicines. https:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/. Accessed 1 July 2020."},{"key":"30","unstructured":"30 Hitchings A, Lonsdale D, Burrage D, Baker E. <i>Top 100 Drugs: Clinical Pharmacology and Practical Prescribing (2nd ed.)<\/i>. Elsevier, 2018; 22\u201323."}],"container-title":["Journal of Clinical Biochemistry and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/68\/3\/68_20-112\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T03:59:01Z","timestamp":1619841541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/68\/3\/68_20-112\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3164\/jcbn.20-112","relation":{},"ISSN":["0912-0009","1880-5086"],"issn-type":[{"value":"0912-0009","type":"print"},{"value":"1880-5086","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}